TWI277651B - New use of some lactobacillus strains in treating allergy - Google Patents
New use of some lactobacillus strains in treating allergy Download PDFInfo
- Publication number
- TWI277651B TWI277651B TW091119957A TW91119957A TWI277651B TW I277651 B TWI277651 B TW I277651B TW 091119957 A TW091119957 A TW 091119957A TW 91119957 A TW91119957 A TW 91119957A TW I277651 B TWI277651 B TW I277651B
- Authority
- TW
- Taiwan
- Prior art keywords
- ccrc
- lactobacillus
- lactic acid
- strain
- bulgaricus
- Prior art date
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 30
- 230000007815 allergy Effects 0.000 title claims abstract description 27
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 17
- 241000186660 Lactobacillus Species 0.000 title claims description 20
- 229940039696 lactobacillus Drugs 0.000 title claims description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 98
- 239000004310 lactic acid Substances 0.000 claims abstract description 50
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 49
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims abstract description 31
- 230000028327 secretion Effects 0.000 claims abstract description 24
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 18
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 18
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 18
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 14
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 14
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 14
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 8
- 230000004936 stimulating effect Effects 0.000 claims abstract description 7
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 claims abstract 15
- 241000894006 Bacteria Species 0.000 claims description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 9
- 238000011161 development Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 3
- 241000218587 Lactobacillus paracasei subsp. paracasei Species 0.000 abstract 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 16
- 210000004698 lymphocyte Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 239000013642 negative control Substances 0.000 description 10
- 244000199866 Lactobacillus casei Species 0.000 description 9
- 235000013958 Lactobacillus casei Nutrition 0.000 description 9
- 235000013351 cheese Nutrition 0.000 description 9
- 229940017800 lactobacillus casei Drugs 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 230000002327 eosinophilic effect Effects 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000021185 dessert Nutrition 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000024833 regulation of cytokine production Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000260546 Carpoglyphus lactis Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 101150044453 Y gene Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 210000005025 intestinal intraepithelial lymphocyte Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW091119957A TWI277651B (en) | 2002-09-02 | 2002-09-02 | New use of some lactobacillus strains in treating allergy |
| JP2003310760A JP2004091491A (ja) | 2002-09-02 | 2003-09-02 | アレルギーを処置する際のいくつかのＬａｃｔｏｂａｃｉｌｌｕｓ株の新規使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW091119957A TWI277651B (en) | 2002-09-02 | 2002-09-02 | New use of some lactobacillus strains in treating allergy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI277651B true TWI277651B (en) | 2007-04-01 |
Family
ID=32067572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW091119957A TWI277651B (en) | 2002-09-02 | 2002-09-02 | New use of some lactobacillus strains in treating allergy |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2004091491A (enExample) |
| TW (1) | TWI277651B (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102597214A (zh) * | 2009-07-22 | 2012-07-18 | Cj第一制糖株式会社 | 新型植物乳杆菌及含该植物乳杆菌的组合物 |
| CN102597216A (zh) * | 2009-10-28 | 2012-07-18 | Cj第一制糖株式会社 | 新型植物乳杆菌及其组合物 |
| CN102292431B (zh) * | 2008-12-03 | 2014-02-19 | Cj第一制糖株式会社 | 一种植物乳杆菌及含该植物乳杆菌的组合物 |
| CN102597215B (zh) * | 2009-07-14 | 2014-06-25 | Cj第一制糖株式会社 | 新型植物乳杆菌及含该植物乳杆菌的组合物 |
| TWI453281B (zh) * | 2012-03-28 | 2014-09-21 | New Bellus Entpr Co Ltd | 抗過敏之乳酸菌及其組合物 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE421256T1 (de) * | 2003-03-13 | 2009-02-15 | Kirin Holdings Kk | Probiotische zusammensetzung |
| CA2599909C (en) | 2005-03-03 | 2014-12-02 | Meiji Dairies Corporation | Immune function modulating agents |
| JP2006273783A (ja) * | 2005-03-30 | 2006-10-12 | Musashino Seiyaku Kk | 掻痒の予防及び／又は治療用組成物 |
| KR100745013B1 (ko) | 2006-01-25 | 2007-08-10 | 주식회사 알엔에이 | 알러지 질환 예방 및 치료를 위한 유산균 |
| TWI386163B (zh) * | 2007-01-05 | 2013-02-21 | Promd Biotech Co Ltd | 抗過敏之乳酸菌 |
| TWI356680B (en) * | 2007-01-05 | 2012-01-21 | Promd Biotech Co Ltd | Anti-allergy lactic acid bacteria |
-
2002
- 2002-09-02 TW TW091119957A patent/TWI277651B/zh not_active IP Right Cessation
-
2003
- 2003-09-02 JP JP2003310760A patent/JP2004091491A/ja active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102292431B (zh) * | 2008-12-03 | 2014-02-19 | Cj第一制糖株式会社 | 一种植物乳杆菌及含该植物乳杆菌的组合物 |
| CN102597215B (zh) * | 2009-07-14 | 2014-06-25 | Cj第一制糖株式会社 | 新型植物乳杆菌及含该植物乳杆菌的组合物 |
| CN102597214A (zh) * | 2009-07-22 | 2012-07-18 | Cj第一制糖株式会社 | 新型植物乳杆菌及含该植物乳杆菌的组合物 |
| CN102597216A (zh) * | 2009-10-28 | 2012-07-18 | Cj第一制糖株式会社 | 新型植物乳杆菌及其组合物 |
| CN102597216B (zh) * | 2009-10-28 | 2015-01-07 | Cj第一制糖株式会社 | 新型植物乳杆菌及其组合物 |
| TWI453281B (zh) * | 2012-03-28 | 2014-09-21 | New Bellus Entpr Co Ltd | 抗過敏之乳酸菌及其組合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004091491A (ja) | 2004-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Betsi et al. | Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials | |
| JP4942831B2 (ja) | 抗アレルギー用組成物 | |
| CN118546812A (zh) | 副干酪乳杆菌菌株及其用途 | |
| CN102168043B (zh) | 可作为免疫调节剂的副干酪乳酸杆菌lt12 | |
| CN102399718B (zh) | 副干酪乳酸杆菌株gmnl‑133、用于改善异位性皮肤炎或其它过敏疾病的组合物及其用途 | |
| TWI277651B (en) | New use of some lactobacillus strains in treating allergy | |
| US20040047849A1 (en) | Use of some lactobacillus strains in treating allergy | |
| KR102106737B1 (ko) | 면역증강 활성을 가진 락토바실러스 퍼멘텀 BioE LF11 사균체를 포함하는 면역증강 조성물 | |
| CN103550258B (zh) | 乳酸菌株调节免疫反应的用途 | |
| JP2003514869A (ja) | アレルギー性疾患の処置のための組成物および方法 | |
| US20140288159A1 (en) | Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human | |
| CN100396771C (zh) | 新的微生物株类干酪乳杆菌gm-080及其治疗过敏相关疾病的用途 | |
| TWI398259B (zh) | 副乾酪乳酸桿菌株ｇｍｎｌ－１３３用於改善異位性皮膚炎或其他過敏疾病之組合物及其用途 | |
| CN1329505C (zh) | 发酵乳酸杆菌GM－090及其在生产刺激INF－γ分泌及/或治疗过敏的药物中的用途 | |
| JP2023037613A (ja) | 乳酸菌含有組成物 | |
| TWI509069B (zh) | 具有免疫調節及抗過敏作用的乳酸菌 | |
| TW201106957A (en) | The new strain of Lactobacillus plantarum LP28 and its use in treating allergy | |
| Hyung et al. | Therapeutic effects of orally administered CJLP55 for atopic dermatitis via the regulation of immune response | |
| JP4847038B2 (ja) | ラクトバチルス・パラカゼイの新規微生物株ｇｍ−０８０及びアレルギー関連疾患を処置するためのその使用 | |
| CN1498627A (zh) | 乳酸杆菌菌株在治疗过敏中之新用途 | |
| JP4823503B2 (ja) | Ｌａｃｔｏｂａｃｉｌｌｕｓｆｅｒｍｅｎｔｕｍの新規微生物株ＧＭ−０９０、およびＩＦＮ−γ分泌の刺激および／またはアレルギーの処置のためのその使用。 | |
| Tsai et al. | Oral administration of multiple lactic acid bacteria strains suppressed allergic responses IgE in an ovalbumin-induced allergy BALB/c mouse model | |
| TWI886566B (zh) | 新穎副乾酪乳桿菌副乾酪亞種ａｐｌ００８、其組合物及用途 | |
| TWI342217B (en) | Anti-allergy microbe, compositions thereof and methods for stimulating cells to secrete interferon-γ using the microbe | |
| TWI351962B (en) | Use of selected lactic acid bacteria for reducing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |